Aclarion (ACON) vs BioNexus Gene Lab (BGLC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclarion is the larger company by market cap ($6.8 million vs $3.9 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ACON | BGLC |
|---|---|---|
| Share price | $2.35 | $1.33 |
| Market cap | $6.77M | $3.89M |
| 1-day change | 0.00% | -1.56% |
| EPS (TTM) | $-7.38 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.03 | $5.89 |
| 52-week low | $1.95 | $1.07 |
| Distance from 52-week high | -80.47% | -77.48% |
| Average volume | 52.63K | 11.08K |
| Shares outstanding | 2.88M | 2.93M |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ACON vs BGLC FAQ
Which is bigger, Aclarion or BioNexus Gene Lab?
Aclarion (ACON) is larger, with a market capitalization of $6.77M compared with $3.89M for BioNexus Gene Lab (BGLC).
Are Aclarion and BioNexus Gene Lab in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.